1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; 67:7–30.
2. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006; 95:Suppl 1. S161–S192.
3. Polyzos A, Tsavaris N, Kosmas C, Giannikos L, Katsikas M, Kalahanis N, et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology. 1999; 56:291–296.
4. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016; CD005340.
5. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354:34–43.
6. Trimble EL, Christian MC. National Cancer Institute-United States strategy regarding intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2008; 18:Suppl 1. 26–28.
7. Naumann RW, Sukumvanich P, Edwards RP. Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer. Gynecol Oncol. 2009; 114:37–41.
8. Fairfield KM, Murray K, LaChance JA, Wierman HR, Earle CC, Trimble EL, et al. Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer. Gynecol Oncol. 2014; 134:473–477.
9. Landrum LM, Hyde J Jr, Mannel RS, McMeekin DS, Moore KN, Walker JL. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2011; 122:527–531.
10. Koo YJ, Lim KT. Toxicity of intraperitoneal chemotherapy and risk factors for severe toxicity in optimally debulked ovarian cancer patients. Taiwan J Obstet Gynecol. 2015; 54:275–279.
11. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009; 42:377–381.
13. Crim A, Rowland M, Ruskin R, Dvorak J, Greenwade M, Walter A, et al. Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. Gynecol Oncol. 2017; 146:268–272.
14. Neuwirth MG, Bartlett EK, Roses RE, Fraker DL, Kelz RR, Karakousis GC. Obesity is not associated with increased morbidity in patients undergoing cytoreductive surgery with intraperitoneal chemotherapy. J Surg Oncol. 2016; 114:619–624.
15. Davis M, Aviki E, Rauh-Hain JA, Worley M Jr, Berkowitz R, Schorge J, et al. Investigating the impact of body mass index on intraperitoneal chemotherapy outcomes in ovarian and fallopian tube cancer. Int J Gynecol Cancer. 2016; 26:1033–1040.
16. AlHilli MM, Tran CW, Langstraat CL, Martin JR, Weaver AL, McGree ME, et al. Risk-scoring model for prediction of non-home discharge in epithelial ovarian cancer patients. J Am Coll Surg. 2013; 217:507–515.
17. Robinson TN, Wallace JI, Wu DS, Wiktor A, Pointer LF, Pfister SM, et al. Accumulated frailty characteristics predict postoperative discharge institutionalization in the geriatric patient. J Am Coll Surg. 2011; 213:37–42.
18. Landrum LM, Gold MA, Moore KN, Myers TK, McMeekin DS, Walker JL. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol. 2008; 108:342–347.
19. Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006; 100:27–32.
20. Bouchard-Fortier G, Rosen B, Vyarvelska I, Pasetka M, Covens A, Gien LT, et al. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer. Gynecol Oncol. 2016; 140:36–41.
21. Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D. Gynecologic Oncology Group. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007; 25:437–443.
22. Makhija S, Leitao M, Sabbatini P, Bellin N, Almadrones L, Leon L, et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol. 2001; 81:77–81.
23. Milczek T, Klasa-Mazurkiewicz D, Wydra D. Complications associated with 9-10Fr venous access port use in adjuvant intraperitoneal chemotherapy after a cytoreductive surgery in ovarian cancer patients. Adv Med Sci. 2015; 60:216–219.
24. Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015; 33:1460–1466.
25. Suidan RS, Zhou Q, Iasonos A, O'Cearbhaill RE, Chi DS, Long Roche KC, et al. Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2015; 25:599–606.